|
Market Closed -
Nasdaq
01:30:00 29/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 23.23 USD | +1.00% |
|
+1.37% | -49.83% |
| 20/10 | Collegium Pharmaceutical Settles Nucynta Patent Litigation for $17 Million | MT |
| 09/10 | Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says | MT |
| Market Cap | 76Cr 68Cr 63Cr 57Cr 106.14Cr 7.2TCr 107.43Cr 750.05Cr 298.75Cr 3.77TCr 283.8Cr 277.81Cr 12TCr | P/E 2026 * |
20.8x | P/E 2027 * | 6.5x |
|---|---|---|---|---|---|
| Enterprise Value | 76Cr 68Cr 63Cr 57Cr 106.14Cr 7.2TCr 107.43Cr 750.05Cr 298.75Cr 3.77TCr 283.8Cr 277.81Cr 12TCr | EV / Sales 2026 * |
0.91x | EV / Sales 2027 * | 0.9x |
| Free-Float |
77.39% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| COLL | Delayed | |
CBOE
| COLL | Real-time | |
|
Boerse Muenchen
| 354 | Real-time | |
|
Deutsche Boerse AG
| 354 | Delayed | |
|
Börse Stuttgart
| 354 | Delayed | |
|
Tradegate
| 354 | Real-time |
Last Transcript: Collegium Pharmaceutical, Inc.
| 1 day | +1.00% | ||
| 1 week | +1.37% | ||
| Current month | +6.46% | ||
| 1 month | +2.65% | ||
| 3 months | -35.29% | ||
| 6 months | -29.20% | ||
| Current year | -49.83% |
| 1 week | 22.15 |  | 23.52 |
| 1 month | 21.43 | | 24.04 |
| Current year | 21.43 | | 49.31 |
| 1 year | 21.43 | | 50.79 |
| 3 years | 21.11 | | 50.79 |
| 5 years | 14.04 | | 50.79 |
| 10 years | 7.37 | | 50.79 |
| Manager | Title | Age | Since |
|---|---|---|---|
Vikram Karnani
CEO | Chief Executive Officer | 51 | 12/11/2024 |
Colleen Tupper
DFI | Director of Finance/CFO | 50 | 24/05/2021 |
Thomas Smith
CTO | Chief Tech/Sci/R&D Officer | 65 | 23/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Gino Santini
CHM | Chairman | 69 | 15/05/2025 |
John Freund
BRD | Director/Board Member | 72 | 01/02/2014 |
Garen Bohlin
BRD | Director/Board Member | 78 | 01/01/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/05/26 | Sell | Director | -20 | 0.0001% | ||
| 15/05/26 | Exercice | Director | 21,527 | 0.0664% | ||
| 14/05/26 | Free | Director | 8,741 | 0.0270% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.00% | +1.37% | -34.40% | +9.78% | 75Cr | |
| +0.50% | +1.38% | +57.09% | +129.96% | 1,14300Cr | |
| +0.86% | +5.14% | +45.00% | +86.15% | 65TCr | |
| -0.14% | +0.42% | +25.69% | +105.85% | 51TCr | |
| -0.05% | +1.73% | +52.74% | +67.74% | 38TCr | |
| -0.63% | -5.97% | +61.93% | +37.06% | 35TCr | |
| +0.34% | +1.84% | +30.70% | +54.27% | 29TCr | |
| -0.45% | +1.19% | +2.89% | +26.08% | 26TCr | |
| +0.87% | +3.08% | +54.69% | +72.74% | 24TCr | |
| +0.08% | +3.67% | +35.05% | +107.78% | 20TCr | |
| Average | +0.24% | +1.44% | +33.14% | +69.74% | 40.28TCr | |
| Weighted average by Cap. | +0.25% | +1.55% | +44.48% | +89.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 83Cr 75Cr 69Cr 63Cr 116.93Cr 7.93TCr 118.34Cr 826.26Cr 329.1Cr 4.15TCr 312.63Cr 306.03Cr 13TCr | 84Cr 76Cr 70Cr 63Cr 118.53Cr 8.04TCr 119.96Cr 837.58Cr 333.61Cr 4.21TCr 316.92Cr 310.23Cr 13TCr |
| Net income | 2.87Cr 2.58Cr 2.38Cr 2.16Cr 4.03Cr 273.59Cr 4.08Cr 28Cr 11Cr 143.16Cr 11Cr 11Cr 454.5Cr | 8.33Cr 7.48Cr 6.91Cr 6.26Cr 12Cr 793.64Cr 12Cr 83Cr 33Cr 415.3Cr 31Cr 31Cr 1.32TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/26/28 | $23.23 | +1.00% | 4,06,091 |
| 27/26/27 | $23.00 | -0.90% | 4,86,611 |
| 26/26/26 | $23.21 | +1.09% | 5,18,254 |
| 23/26/23 | $22.96 | -2.30% | 6,62,374 |
| 22/26/22 | $23.50 | +2.55% | 7,38,765 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- COLL Stock
Select your edition
All financial news and data tailored to specific country editions
